<p>Calamos Wealth Management LLC 在最近向证券交易委员会（SEC）提交的 13F 文件中表示，在第三季度将其在安进公司（NASDAQ:AMGN - 免费报告）的持股比例提高了 136.1%。该公司在此期间购买了额外的 3,351 股后，持有 5,813 股这家医疗研究公司的股票。根据其最近向证券交易委员会（SEC）提交的文件，Calamos Wealth Management LLC 在安进的持股价值为 1,640,000 美元。</p>
<ul>
<li>3 家医疗巨头刚刚提高了股息——看看谁支付得最多</li>
</ul>
<p>其他一些对冲基金最近也增加或减少了在 AMGN 的持股。Legacy Investment Solutions LLC 在第二季度购买了安进的新股份，价值约 27,000 美元。CBIZ Investment Advisory Services LLC 在第一季度将其在安进的持股比例提高了 1,214.3%。CBIZ Investment Advisory Services LLC 目前持有 92 股这家医疗研究公司的股票，价值 29,000 美元，此前在上个季度购买了额外的 85 股。Evelyn Partners Investment Management LLP 在第二季度获得了安进的新职位，价值约 32,000 美元。霍华德·休斯医学研究所（Howard Hughes Medical Institute）在第二季度获得了安进的新职位，价值约 32,000 美元。最后，Quaker Wealth Management LLC 在第二季度将其在安进的持股比例提高了 200.0%。Quaker Wealth Management LLC 目前持有 120 股这家医疗研究公司的股票，价值 34,000 美元，此前在上个季度购买了额外的 240 股。76.50% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>安进价格表现</h2>
<p>周三，NASDAQ AMGN 的股票开盘价为 328.49 美元。该公司的 50 日简单移动平均线为 324.05 美元，200 日简单移动平均线为 302.22 美元。该公司的速动比率为 0.99，流动比率为 1.28，债务与股本比率为 5.45。该股票的市值为 1,768.9 亿美元，市盈率为 25.39，市盈增长比率为 3.06，贝塔值为 0.45。安进公司的 52 周低点为 257.05 美元，52 周高点为 346.38 美元。</p>
<ul>
<li>5 家医疗公司值得关注，因为行业轮动正在全面展开</li>
</ul>
<p>安进（NASDAQ:AMGN - 获取免费报告）最近在 11 月 4 日（星期二）发布了季度财报。这家医疗研究公司报告的每股收益为 5.64 美元，超出分析师一致预期的 5.01 美元，超出幅度为 0.63 美元。该公司在本季度的收入为 95.6 亿美元，而分析师预期为 89.8 亿美元。安进的净利润率为 19.47%，股本回报率为 162.59%。安进的季度收入同比增长 12.4%。在去年同期，该公司每股收益为 5.58 美元。安进已将其 2025 财年的指导目标设定为 20.600-21.400 每股收益。平均而言，股票分析师预测安进公司在当前财年将发布 20.62 美元的每股收益。</p>
<h2>安进增加股息</h2>
<p>该公司最近还宣布了一项季度股息，将于 3 月 6 日（星期五）支付。记录在案的投资者将在 2 月 13 日（星期五）获得 2.52 美元的股息。这比安进之前的季度股息 2.38 美元有所增加。这代表着每年 10.08 美元的股息和 3.1% 的股息收益率。该股息的除息日期为 2 月 13 日（星期五）。安进的派息比率为 73.57%。</p>
<h2>内部买卖</h2>
<ul>
<li>安进股票：在财报超预期后，新的历史高点即将到来</li>
</ul>
<p>在其他安进新闻中，副总裁 Nancy A. Grygiel 于 11 月 20 日（星期四）出售了 3,139 股该公司的股票。股票以平均价格 337.26 美元出售，总价值为 1,058,659.14 美元。交易完成后，这位高级副总裁直接持有 7,225 股公司股票，价值 2,436,703.50 美元。这笔交易代表其持股比例减少了 30.29%。该出售在向证券交易委员会的法律文件中披露，文件可通过此超链接获取。此外，执行副总裁 Murdo Gordon 于 11 月 12 日（星期三）出售了 6,879 股公司的股票。股票以平均价格 336.83 美元出售，总交易额为 2,317,053.57 美元。交易完成后，该执行副总裁直接持有 41,923 股公司股票，价值约 14,120,924.09 美元。这笔交易代表其持股比例减少了 14.10%。该出售的 SEC 文件提供了更多信息。在过去的 90 天里，内部人士已出售 10,908 股公司股票，价值 3,674,966 美元。0.69% 的股票由公司内部人士持有。</p>
<h2>华尔街分析师观点</h2>
<p>AMGN 最近成为多份分析师报告的主题。DZ Bank 在 11 月 10 日（星期一）的研究报告中将安进的目标价格从 335.00 美元提高至 364.00 美元。高盛集团在 11 月 25 日（星期二）的报告中重申了对安进股票的 “买入” 评级。汇丰银行在 12 月 10 日（星期三）的研究报告中重申了 “买入” 评级，并将安进的目标价格设定为 425.00 美元。雷蒙德·詹姆斯金融公司在 9 月 3 日（星期三）的研究报告中对安进股票进行了覆盖。他们对该公司的评级为 “市场表现”。最后，摩根士丹利在 12 月 12 日（星期五）的研究报告中将安进的目标价格从 329.00 美元下调至 304.00 美元，并对该公司设定了 “持平” 评级。一位研究分析师对该股票给予了强烈买入评级，十一位分析师给予了买入评级，十位分析师给予了持有评级，一位分析师对该公司的股票给予了卖出评级。根据 MarketBeat.com 的数据，安进目前的共识评级为 “适度买入”，共识目标价格为 334.14 美元。</p>
<p><strong>查看我们最新的 AMGN 股票分析</strong></p>
<h2>安进简介</h2>
<p>（免费报告）</p>
<p>安进公司（Amgen Inc）纳斯达克代码：AMGN 是一家成立于 1980 年的全球生物技术公司，总部位于加利福尼亚州的千橡市。该公司专注于发现、开发、制造和提供针对严重疾病的人类治疗药物。安进的工作重点是基于细胞和分子生物学的生物药物，强调将人类遗传学和蛋白质科学的进展转化为患者的治疗方案。</p>
<p>安进的商业产品组合历史上包括用于肿瘤学、支持性护理、肾脏病、骨骼健康和心血管疾病的生物制剂。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票，胜过安进</li>
<li>请勿删除，立即阅读</li>
<li>崩盘已经开始（大多数人尚未察觉）</li>
<li>警报：在 2026 年 1 月之前抛售这五只股票！</li>
<li>[无脑黄金投资]：“给我一个更好的投资。”</li>
<li>投资者警报：微型 “3 美元人工智能奇迹股票” 即将腾飞</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU1HTg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU1HTg"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在安进吗？</h2>
<p>在考虑安进之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而安进并不在名单上。</p>
<p>虽然安进目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

安进

<p>Calamos Wealth Management LLC 在第三季度将其在安进（Amgen Inc.）的持股增加了 136.1%，目前持有 5,813 股，价值 164 万美元。其他对冲基金也调整了在安进的持仓。该公司报告第三季度每股收益为 5.64 美元，超出预期，收入为 95.6 亿美元。安进宣布季度股息为 2.52 美元，较之前的 2.38 美元有所上升，股息收益率为 3.1%。内部人士进行了股票出售，部分高管出售了大量股份。安进的股票表现显示市值为 1768.9 亿美元，市盈率为 25.39</p>

<p>Calamos Wealth Management LLC lifted its position in Amgen Inc. (NASDAQ:AMGN - Free Report) by 136.1% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,813 shares of the medical research company's stock after purchasing an additional 3,351 shares during the period. Calamos Wealth Management LLC's holdings in Amgen were worth $1,640,000 as of its most recent filing with the Securities and Exchange Commission (SEC).</p>
<div class="lb-trans"><p>Calamos Wealth Management LLC 在最近向证券交易委员会（SEC）提交的 13F 文件中表示，在第三季度将其在安进公司（NASDAQ:AMGN - 免费报告）的持股比例提高了 136.1%。该公司在此期间购买了额外的 3,351 股后，持有 5,813 股这家医疗研究公司的股票。根据其最近向证券交易委员会（SEC）提交的文件，Calamos Wealth Management LLC 在安进的持股价值为 1,640,000 美元。</p>
</div><ul>
<li>3 Healthcare Giants Just Raised Dividends—Here’s Who Pays the Most</li>
</ul>
<div class="lb-trans"><ul>
<li>3 家医疗巨头刚刚提高了股息——看看谁支付得最多</li>
</ul>
</div><p>A number of other hedge funds have also recently added to or reduced their stakes in AMGN. Legacy Investment Solutions LLC purchased a new stake in shares of Amgen during the 2nd quarter worth about $27,000. CBIZ Investment Advisory Services LLC increased its stake in shares of Amgen by 1,214.3% in the 1st quarter. CBIZ Investment Advisory Services LLC now owns 92 shares of the medical research company's stock valued at $29,000 after purchasing an additional 85 shares in the last quarter. Evelyn Partners Investment Management LLP acquired a new position in Amgen in the 2nd quarter worth about $32,000. Howard Hughes Medical Institute acquired a new position in Amgen in the 2nd quarter worth about $32,000. Finally, Quaker Wealth Management LLC boosted its position in Amgen by 200.0% during the second quarter. Quaker Wealth Management LLC now owns 120 shares of the medical research company's stock worth $34,000 after purchasing an additional 240 shares in the last quarter. 76.50% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>其他一些对冲基金最近也增加或减少了在 AMGN 的持股。Legacy Investment Solutions LLC 在第二季度购买了安进的新股份，价值约 27,000 美元。CBIZ Investment Advisory Services LLC 在第一季度将其在安进的持股比例提高了 1,214.3%。CBIZ Investment Advisory Services LLC 目前持有 92 股这家医疗研究公司的股票，价值 29,000 美元，此前在上个季度购买了额外的 85 股。Evelyn Partners Investment Management LLP 在第二季度获得了安进的新职位，价值约 32,000 美元。霍华德·休斯医学研究所（Howard Hughes Medical Institute）在第二季度获得了安进的新职位，价值约 32,000 美元。最后，Quaker Wealth Management LLC 在第二季度将其在安进的持股比例提高了 200.0%。Quaker Wealth Management LLC 目前持有 120 股这家医疗研究公司的股票，价值 34,000 美元，此前在上个季度购买了额外的 240 股。76.50% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>Amgen Price Performance</h2>
<div class="lb-trans"><h2>安进价格表现</h2>
</div><p>Shares of NASDAQ AMGN opened at $328.49 on Wednesday. The firm has a 50-day simple moving average of $324.05 and a 200-day simple moving average of $302.22. The company has a quick ratio of 0.99, a current ratio of 1.28 and a debt-to-equity ratio of 5.45. The stock has a market capitalization of $176.89 billion, a price-to-earnings ratio of 25.39, a price-to-earnings-growth ratio of 3.06 and a beta of 0.45. Amgen Inc. has a 52 week low of $257.05 and a 52 week high of $346.38.</p>
<div class="lb-trans"><p>周三，NASDAQ AMGN 的股票开盘价为 328.49 美元。该公司的 50 日简单移动平均线为 324.05 美元，200 日简单移动平均线为 302.22 美元。该公司的速动比率为 0.99，流动比率为 1.28，债务与股本比率为 5.45。该股票的市值为 1,768.9 亿美元，市盈率为 25.39，市盈增长比率为 3.06，贝塔值为 0.45。安进公司的 52 周低点为 257.05 美元，52 周高点为 346.38 美元。</p>
</div><ul>
<li>5 Healthcare Names to Watch as Sector Rotation Is in Full Swing</li>
</ul>
<div class="lb-trans"><ul>
<li>5 家医疗公司值得关注，因为行业轮动正在全面展开</li>
</ul>
</div><p>Amgen (NASDAQ:AMGN - Get Free Report) last posted its quarterly earnings results on Tuesday, November 4th. The medical research company reported $5.64 earnings per share for the quarter, topping analysts' consensus estimates of $5.01 by $0.63. The firm had revenue of $9.56 billion for the quarter, compared to analyst estimates of $8.98 billion. Amgen had a net margin of 19.47% and a return on equity of 162.59%. Amgen's quarterly revenue was up 12.4% on a year-over-year basis. During the same period in the previous year, the business posted $5.58 earnings per share. Amgen has set its FY 2025 guidance at 20.600-21.400 EPS. On average, equities analysts predict that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>安进（NASDAQ:AMGN - 获取免费报告）最近在 11 月 4 日（星期二）发布了季度财报。这家医疗研究公司报告的每股收益为 5.64 美元，超出分析师一致预期的 5.01 美元，超出幅度为 0.63 美元。该公司在本季度的收入为 95.6 亿美元，而分析师预期为 89.8 亿美元。安进的净利润率为 19.47%，股本回报率为 162.59%。安进的季度收入同比增长 12.4%。在去年同期，该公司每股收益为 5.58 美元。安进已将其 2025 财年的指导目标设定为 20.600-21.400 每股收益。平均而言，股票分析师预测安进公司在当前财年将发布 20.62 美元的每股收益。</p>
</div><h2>Amgen Increases Dividend</h2>
<div class="lb-trans"><h2>安进增加股息</h2>
</div><p>The business also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, February 13th will be issued a $2.52 dividend. This is a boost from Amgen's previous quarterly dividend of $2.38. This represents a $10.08 annualized dividend and a dividend yield of 3.1%. The ex-dividend date of this dividend is Friday, February 13th. Amgen's payout ratio is 73.57%.</p>
<div class="lb-trans"><p>该公司最近还宣布了一项季度股息，将于 3 月 6 日（星期五）支付。记录在案的投资者将在 2 月 13 日（星期五）获得 2.52 美元的股息。这比安进之前的季度股息 2.38 美元有所增加。这代表着每年 10.08 美元的股息和 3.1% 的股息收益率。该股息的除息日期为 2 月 13 日（星期五）。安进的派息比率为 73.57%。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>内部买卖</h2>
</div><ul>
<li>Amgen Stock: New All-Time Highs Ahead After Earnings Beat</li>
</ul>
<div class="lb-trans"><ul>
<li>安进股票：在财报超预期后，新的历史高点即将到来</li>
</ul>
</div><p>In other Amgen news, SVP Nancy A. Grygiel sold 3,139 shares of the firm's stock in a transaction on Thursday, November 20th. The stock was sold at an average price of $337.26, for a total value of $1,058,659.14. Following the completion of the sale, the senior vice president directly owned 7,225 shares of the company's stock, valued at $2,436,703.50. This trade represents a 30.29% decrease in their position. The sale was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is available through this hyperlink. Also, EVP Murdo Gordon sold 6,879 shares of the business's stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $336.83, for a total transaction of $2,317,053.57. Following the transaction, the executive vice president directly owned 41,923 shares in the company, valued at approximately $14,120,924.09. The trade was a 14.10% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 10,908 shares of company stock worth $3,674,966. 0.69% of the stock is owned by corporate insiders.</p>
<div class="lb-trans"><p>在其他安进新闻中，副总裁 Nancy A. Grygiel 于 11 月 20 日（星期四）出售了 3,139 股该公司的股票。股票以平均价格 337.26 美元出售，总价值为 1,058,659.14 美元。交易完成后，这位高级副总裁直接持有 7,225 股公司股票，价值 2,436,703.50 美元。这笔交易代表其持股比例减少了 30.29%。该出售在向证券交易委员会的法律文件中披露，文件可通过此超链接获取。此外，执行副总裁 Murdo Gordon 于 11 月 12 日（星期三）出售了 6,879 股公司的股票。股票以平均价格 336.83 美元出售，总交易额为 2,317,053.57 美元。交易完成后，该执行副总裁直接持有 41,923 股公司股票，价值约 14,120,924.09 美元。这笔交易代表其持股比例减少了 14.10%。该出售的 SEC 文件提供了更多信息。在过去的 90 天里，内部人士已出售 10,908 股公司股票，价值 3,674,966 美元。0.69% 的股票由公司内部人士持有。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><p>AMGN has been the subject of a number of recent analyst reports. DZ Bank boosted their price objective on Amgen from $335.00 to $364.00 in a research report on Monday, November 10th. The Goldman Sachs Group reissued a &#34;buy&#34; rating on shares of Amgen in a report on Tuesday, November 25th. HSBC restated a &#34;buy&#34; rating and set a $425.00 price objective on shares of Amgen in a research report on Wednesday, December 10th. Raymond James Financial initiated coverage on shares of Amgen in a research note on Wednesday, September 3rd. They set a &#34;market perform&#34; rating for the company. Finally, Morgan Stanley reduced their price target on shares of Amgen from $329.00 to $304.00 and set an &#34;equal weight&#34; rating for the company in a research report on Friday, December 12th. One research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, Amgen currently has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $334.14.</p>
<div class="lb-trans"><p>AMGN 最近成为多份分析师报告的主题。DZ Bank 在 11 月 10 日（星期一）的研究报告中将安进的目标价格从 335.00 美元提高至 364.00 美元。高盛集团在 11 月 25 日（星期二）的报告中重申了对安进股票的 “买入” 评级。汇丰银行在 12 月 10 日（星期三）的研究报告中重申了 “买入” 评级，并将安进的目标价格设定为 425.00 美元。雷蒙德·詹姆斯金融公司在 9 月 3 日（星期三）的研究报告中对安进股票进行了覆盖。他们对该公司的评级为 “市场表现”。最后，摩根士丹利在 12 月 12 日（星期五）的研究报告中将安进的目标价格从 329.00 美元下调至 304.00 美元，并对该公司设定了 “持平” 评级。一位研究分析师对该股票给予了强烈买入评级，十一位分析师给予了买入评级，十位分析师给予了持有评级，一位分析师对该公司的股票给予了卖出评级。根据 MarketBeat.com 的数据，安进目前的共识评级为 “适度买入”，共识目标价格为 334.14 美元。</p>
</div><p><strong>View Our Latest Stock Analysis on AMGN</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 AMGN 股票分析</strong></p>
</div><h2>Amgen Profile</h2>
<div class="lb-trans"><h2>安进简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Amgen Inc NASDAQ: AMGN is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.</p>
<div class="lb-trans"><p>安进公司（Amgen Inc）纳斯达克代码：AMGN 是一家成立于 1980 年的全球生物技术公司，总部位于加利福尼亚州的千橡市。该公司专注于发现、开发、制造和提供针对严重疾病的人类治疗药物。安进的工作重点是基于细胞和分子生物学的生物药物，强调将人类遗传学和蛋白质科学的进展转化为患者的治疗方案。</p>
</div><p>Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.</p>
<div class="lb-trans"><p>安进的商业产品组合历史上包括用于肿瘤学、支持性护理、肾脏病、骨骼健康和心血管疾病的生物制剂。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Amgen</li>
<li>Do not delete, read immediately</li>
<li>The Crash Has Already Started (Most Just Don’t See It Yet)</li>
<li>ALERT: Drop these 5 stocks before January 2026!</li>
<li>[No Brainer Gold Play]: “Show me a better investment.”</li>
<li>INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过安进</li>
<li>请勿删除，立即阅读</li>
<li>崩盘已经开始（大多数人尚未察觉）</li>
<li>警报：在 2026 年 1 月之前抛售这五只股票！</li>
<li>[无脑黄金投资]：“给我一个更好的投资。”</li>
<li>投资者警报：微型 “3 美元人工智能奇迹股票” 即将腾飞</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU1HTg" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=AMGN"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Amgen Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在安进吗？</h2>
</div><p>Before you consider Amgen, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑安进之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amgen wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而安进并不在名单上。</p>
</div><p>While Amgen currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然安进目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Calamos Wealth Management LLC 收购了安进公司 $AMGN 的股票